Angiogenesis and anti-angiogenesis: Perspectives for the treatment of solid tumors

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Van Hinsbergh, Victor W M ^a,b   Collen, Annemie ^a   Koolwijk, Pieter ^a  

^a TNO   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Angiogenesis; Angiogenesis inhibition; Angiogenic growth factors; Endothelium; Matrix degrading proteases; Pancreas

Indexed keywords

ANGIOGENIC FACTOR; CELL ADHESION MOLECULE; CYTOKINE; INTEGRIN; PROTEINASE;

ANGIOGENESIS; CONFERENCE PAPER; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH;

EID: 0032783925     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S60     Document Type: Conference Paper

References (52)

1. Folkman J. Tumor angiogenesis. In: The molecular basis of cancer, Mendelsohn, J., Howley PM, Isreal MA, and Liotta LA, eds, Philadelphia: W.B. Saunders Comp, 1995; 206-32.
2. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997; 349:S13-5.
3. Pluda JM, Parkinson DR. Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Cancer 1996; 78:680-7.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
5. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985; 315:115-22.
6. Folkman J, Watson K, Ingber D et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58-61.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64.
8. Weidner N, Semple JP, Welch WR et al. Tumor Angiogenesis and Metastasis -Correlation in Invasive Breast Carcinoma. N Engl J Med 1991; 324:1-8.
9. Macchiarini P, Fontanini G, Hardin MJ et al. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992; 340:145-6.
10. Weidner N, Carroll PR, Flax J et al. Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Carcinoma. Am J Pathol 1993; 143:401-9.
11. Kim KJ, Li B, Winer J et al. Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth In vivo. Nature 1993; 362:841-4.
12. Hori A, Sasada R, Matsutani E et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991; 51:6180-4.
13. Shalaby F, Rossant J, Yamaguchi TP et al. Failure of blood-island formation and vasculogenesis in Flk-1- deficient mice. Nature 1995; 376:62-6.
14. Fong GH, Rossant, J, Gertsenstein M et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376:66-70.
15. Dvorak HF, Nagy JA, Dvorak JT et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 1988; 133:95-109.
16. Polverini PJ. Macrophage-induced angiogenesis - A review. Macrophage-Derived Cell Regulatory Factors 1989; 1:54-73.
17. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9.
18. Van Hinsbergh VWM, Koolwijk P, Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. In: Regulation of Angiogenesis. Goldberg ID, Rosen EM, eds., Basel: Birkhauser Verlag, 1997;:391-411.
19. Min HY, Doyle LV, Vitt, CR et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996; 56:2428-33.
20. Li H, Lu H, Griscelli, F et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Therapy. 1998; 5:1105-13.
21. Brooks PC, Montgomery AMP, Rosenfeld M et al. Integrin aVb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-64.
22. Friedlander M, Brooks PC, Shaffer RW et al. Definition of two angiogenic pathways by distinct alpha(v) integrins. Science 1995; 270:1500-02.
23. Bugge TH, Suh TT, Flick MJ et al. The receptor for urokinase-type plasminogen activator is not essential for mouse development and fertility. J Biol Chem 1995; 270: 16886-94.
24. Bader BL, Rayburn H, Crowley D et al. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998; 95:507-19.
25. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:1029-39.
26. Montesano R. Regulation of Angiogenesis Invitro. Eur J Clin Invest. 1992; 22:504-15.
27. Pepper MS, Belin D, Montesano R et al. Transforming growth factor-b-1 modulates basic fibroblast growth factor induced proteolytic and angiogenic properties of endothelial cells invitro. J Cell Biol 1990; 111:743-55.
28. Pepper MS. Manipulating angiogenesis - From basic science to the bedside. Arterioscl Thromb Vasc Biol 1997; 17:605-19.
29. Koolwijk P, Van Erck MGM, De Vree WJA et al. Cooperative effect of TNFα, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol. 1996; 132:1177-88.
30. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer Metastasis and Angiogenesis - An Imbalance of Positive and Negative Regulation. Cell 1991; 64:327-36.
31. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-28.
32. O'Reilly MS, Boehm T, Shing, Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-85.
33. Boehm T, Folkman J, Browder T et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 1997; 390:404-7.
34. Fan TPD, Jaggar R, Bicknell R. Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 1995; 16:57-66.
35. Brown P. D. Synthetic inhibitors of matrix metalloproteases. In: Matrix metalloproteinases. Parks WC, Mechan RP, eds, New York: Academic Press, 1998; 243-61.
36. Ingber D, Fujita T, Kishimoto S et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348:555-7.
37. D'Amato PJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-5.
38. D'Amato RJ, Lin CM, Flynn E et al. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994; 91:3964-8.
39. Konerding MA, Miodonski AJ, Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularily: a review. Scanning Microsc 1995; 9:1233-43.
40. Jain RK. Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol 1991; 60:85-100.
41. Burrows FJ, Derbyshire EJ, Tazzari PL et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995; 1:1623-34.
42. Contrino J, Hair G, Kreutzer DL et al. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Med 1996; 2:209-15.
43. Nawroth P, Handley D, Matsueda G et al. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 1988; 168:637-47.
44. Huang X, Molema G, King S et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275:547-50.
45. Brown, LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor land its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53:4727-35.
46. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995; 9:1760-70.
47. Takebayashi Y, Yamada K, Miyadera K et al. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 1996; 32A:1227-32.
48. Shimoyama S, Gansauge F, Gansauge S et al. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res 1996; 56:2703-6.
49. Yamazaki K, Nagao T, Yamaguchi T et al. Expression of basic fibroblast growth factor (FGF-2)-associated with tumour proliferation in human pancreatic carcinoma. Virchows Arch 1997; 431:95-101.
50. Max R, Gerritsen RRCM, Noojjen PTGA et al. Immunohistochemical analysis of integrin alpha v beta 3 expression on tumor- associated vessels of human carcinomas. Int J Cancer 1997; 71:320-24.
51. Ellis LM, Takahashi Y, Fenoglio CJ et al. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998; 34:337-40.
52. Kawarada Y, Ishikura H, Kishimoto T et al. Inhibitory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo. Pancreas 1997; 15:251-7.